Lower Risk Of Dying From Any Cause Over 4 64 Year Median Follow Up Period In Prostate Cancer Patients Who Used Metform

Lower risk of dying from any cause over 4.64 year median follow-up period in prostate cancer patients who used metformin

Lower risk of dying from any cause over 4.64 year median follow-up period in prostate cancer patients who used metformin

Tuesday, August 13, 2013. In an article published online on August 5, 2013 in the Journal of Clinical Oncology, researchers from Toronto report a lower risk of mortality among prostate cancer patients with diabetes who were being treated with the antidiabetic drug metformin in comparison with those who were not being treated with the drug.

David Margal, MD, PhD at the University of Toronto and his associates evaluated information from 3,837 men with prostate cancer aged 66 years and older identified by the Ontario Diabetes Database. An additional database provided information on antidiabetic medications prescribed to the subjects. There were 1,343 deaths over a 4.64 year median follow-up from the time of diagnosis, among which 291 were caused by prostate cancer.

Metformin was used by 32.6% of the men prior to prostate cancer diagnosis and 42.2% following diagnosis. For each six months of metformin use after diagnosis, there was a 24% reduction in the risk of dying from prostate cancer in comparison with nonusers. There was also a 24% reduction in the risk of death from any cause during the first six months of metformin use, which declined to a 7% reduction with longer use. The authors note that metformin was associated with a benefit regardless of cancer treatments being used; which implies that metformin could help improve survival as an adjunct therapy.

Dr Margal and his coauthors suggest that metformin may reduce the risk of dying from prostate cancer by preventing cancer progression. The drug may influence cancer cells indirectly by reducing insulin levels or directly by affecting the proliferation of cancer cells and apoptosis (programmed cell death). "Because prostate cancer is a slow-growing disease, medication exposures postdiagnosis may have an impact on disease progression and survival and thus may be ideal for secondary prevention strategies," they write.

"Our study is among the first to report that cumulative metformin use after prostate cancer diagnosis is associated with improved all-cause and prostate cancer-specific survival among elderly diabetic men," they announce. "We believe an interventional study of the use of metformin to delay progression in prostate cancer is warranted."

What's Hot Highlight

Yet another analysis associates higher vitamin D levels with reduced all-cause mortality

What's Hot

The results of a meta-analysis published on July 24, 2013 in BioMed Central Public Health reveal a reduced risk of dying over 6 to 13.5 years of follow-up among men and women with higher, as compared to lower, vitamin D levels.

Lynne Rush of the National Health Service of Greater Glasgow and Clyde and her associates analyzed the findings of nine studies which provided data on serum 25-hydroxyvitamin D status and mortality for a total of 24,297 adults of varying ages. Over the studies' follow-up periods, 5,324 deaths occurred. After adjusting for several factors, a 19% higher risk of dying from any cause over follow-up was found among those with lower serum vitamin D as compared to higher levels. When the subjects were analyzed according to age, the adjusted risk of dying was 12% higher for subjects with low vitamin D in studies of subjects whose age averaged less than 65 years, and 25% higher for studies whose participants had an average age of over 65 years.

"As far as we are aware, this is the only systematic review and meta-analysis that has specifically investigated whether the apparent association between low vitamin D status and all-cause mortality is age-dependent," the authors announce. "Although a significant increase in all-cause mortality was found in study participants of all ages with low compared to higher 25-hydroxyvitamin D levels, the pooled effect size was lower for studies with participants with an average age of less than 65 years compared to the studies containing older participants."

"Further studies investigating the association between vitamin D deficiency and all-cause mortality in younger adults with adjustment for all important confounders (or using randomised trials of supplementation) are required to clarify this relationship," they conclude.

Free Webinar—You're Invited

Exposing Hidden Health Dangers

Hosted by Michael A. Smith, M.D.

Wednesday, August 21, 2013
7 pm–8 pm ET

Please join Life Extension's webinar highlighting hidden health dangers in our air, soil, water and food. Dr. Mike, Senior Health Scientist at Life Extension, will present research showing how these dangerous chemicals damage our bodies and he will discuss ways to safely and effectively protect you against them. Don't miss this lecture presented by the "country doctor with a city education."

Register Now
Reserve your webinar seat now at:

After registering, you will receive a confirmation e-mail containing information about joining the webinar.

System Requirements

PC-based attendees
Required: Windows® 7, Vista, XP or 2003 Server

Macintosh®-based attendees
Required: Mac OS® X 10.5 or newer

Mobile attendees
Required: iPhone®, iPad®, Android™ phone or Android Tablet

Visit to view past webinars!

Latest Supplements

Endothelial Defense™ with Full-Spectrum Pomegranate, 60 softgels
Item #01498

add to cart

Endothelial Defense™ with Full-Spectrum Pomegranate™ supplies standardized pomegranate and an orally active form of superoxide dismutase to support endothelial health. Both of these components (pomegranate, SOD) have been clinically shown to help with blood flow and age-related changes in endothelial function.

  1. Pomegranate supports healthy blood flow. This standardized pomegranate extract is one of the active components of Endothelial Defense™.
  2. SOD protects against nitric oxide degradation. An orally active superoxide dismutase called GliSODin® has been clinically shown to support healthy arterial function and structure . . . while boosting levels of the body's most powerful antioxidant enzymes.
  3. Pomegranate flower extract and seed oil blend. This blend of pomegranate flower extract and seed oil contains potent polyphenols that provide support for youthful lipid and glucose metabolism and help with inflammatory factors.

POMELLA® Extract is covered under U.S. Patent 7,638,640 and POMELLA® is a registered trademark of Verdure Sciences, Inc. Isocell SA, France is the owner of US Patents Nos. 6,045,809 and 6,426,068B1 and trademark of GliSODin®.

Kyolic® Garlic Formula 102

Cosmesis Ultra Lip Plumper, 0.33 oz.
Item #80116

add to cart

Renowned dermatologist Gary Goldfaden, M.D., has developed novel solutions for the most common skin problems encountered by maturing adults. Based on extensive clinical testing, these formulas are designed with potent antioxidant tea extracts (red, green, and white) to correct specific areas of concern, such as the appearance of darkness and puffiness under the eyes, fine lines, rough skin, loose skin, and more. These products can be used in conjunction with any other skin treatments or products. They are specially formulated exclusively for Life Extension.

Increase volume and lip contour and give better definition to your lip lines. Ultra Lip Plumper uses natural plant-derived irritants to increase lip volume. Natural moisturizers, such as squalene and jojoba oil, smooth lips and lessen the appearance of creases.



Life Extension Update What's Hot
Metformin shows anticancer effect in early breast cancer patients Metformin helps prevent breast cancer growth fueled by estrogen and other compounds
Vitamin D supplementation improves outcome in men with low-risk prostate cancer New studies reveal lower risk of cancer in metformin-treated patients
Metformin shows promise for the treatment of pancreatic cancer Metformin increases treatment response rate of diabetics undergoing chemotherapy
Life Extension Magazine® Health Topics
Can a diabetes drug prevent cancer death? Prostate cancer: overview
Metformin makes headline news Diabetes
The multiple benefits of metformin Cancer adjuvant therapy